Aeterna Zentaris Inc. (NASDAQ: AEZS) announced on June 28th that its Japanese partner Yakult Honsha (“Yakult”) (Tokyo: 2267) has initiated a Phase 1 trial in multiple myeloma, a form of blood cancer, with perifosine, the Company’s oral Akt/PI3K inhibitor drug. Yakult, who are sponsoring and conducting this trial in Japan, reported that a first patient has been treated with perifosine.
Juergen Engel, PhD, President and CEO at Aeterna Zentaris stated:
We would like to thank our partner Yakult for their close collaboration in initiating this important Phase 1 trial in multiple myeloma which is necessary at this time in order to comply with Japan’s specific registration requirements. Perifosine, also currently in a Phase 3 trial in other parts of the world in multiple myeloma for which we expect to reach an interim analysis in the first quarter of next year, remains a key component of our deep pipeline focused on providing novel, targeted treatment options for cancer patients facing unmet medical needs.
Keep AEZS on close watch: recent development should be positively reflected in the share price.
Æterna Zentaris Inc.
1405 du Parc-Technologique Blvd.
Tel: (418) 652-8525
Fax: (418) 652-0881
Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer.The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options.
An affiliate of PennyStockHaven.com receives up to fifteen thousand dollars per month for consulting and advisory services related to Aeterna. Our relationship with this affiliate constitutes a conflict and may affect the objectivity of our profile of the company. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here.